K. Bleasby

发表

Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure

K. Lyons, L. Cohen, G. Salituro, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2012, Bioorganic & medicinal chemistry letters.

A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

In Vitro Evaluation of the Drug Interaction Potential of Doravirine

Meihong Lin, K. Bleasby, G. Chan, 2019, Antimicrobial Agents and Chemotherapy.

Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C

K. Bleasby, Colin D. A. Brown, B. Lauffart, 2001 .

Characterization of MPP+ secretion across human intestinal Caco‐2 cell monolayers: role of P‐glycoprotein and a novel Na+‐dependent organic cation transport mechanism

S. Chauhan, K. Bleasby, Colin D. A. Brown, 2000, British journal of pharmacology.

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease

X. Chu, R. Evers, S. Harper, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

Yongxin Han, S. Gagné, Y. Ducharme, 2011, Bioorganic & medicinal chemistry letters.

Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake

F. Ujjainwalla, M. Braun, Y. S. Tang, 2008, Molecular Pharmacology.

The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3.

Amy G. Aslamkhan, David S. Miller, S. Barros, 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Shiyao Xu, Arthur J Bergman, X. Chu, 2007, Journal of Pharmacology and Experimental Therapeutics.

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

David A. Powell, Lei Zhang, R. Oballa, 2011, Journal of medicinal chemistry.

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters

Meihong Lin, K. Bleasby, M. Hafey, 2021, Viruses.

The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?

X. Chu, R. Evers, K. Bleasby, 2016, Drug Metabolism and Disposition.

Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6)

H. Mohrenweiser, K. Bleasby, J. B. Pritchard, 2005, Journal of Pharmacology and Experimental Therapeutics.

The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers

K. Bleasby, Colin D. A. Brown, A. Dudley, 2000, British journal of pharmacology.

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition

J. Castle, R. Ulrich, C. Roberts, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Species differences in drug transporters and implications for translating preclinical findings to humans

X. Chu, R. Evers, Xiaoyan Chu, 2013, Expert opinion on drug metabolism & toxicology.

Transporters affecting biochemical test results: Creatinine‐drug interactions

X. Chu, R. Evers, K. Bleasby, 2016, Clinical pharmacology and therapy.

In Vitro Techniques to Study Transporter-Based DDI

X. Chu, R. Evers, K. Bleasby, 2010 .

A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats

R. Evers, T. Baillie, D. Dean, 2008 .

Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats.

R. Evers, T. Baillie, D. Dean, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

QSAR Prediction of Passive Permeability in the LLC‐PK1 Cell Line: Trends in Molecular Properties and Cross‐Prediction of Caco‐2 Permeabilities

Andreas Verras, Robert P Sheridan, Edward C Sherer, 2012, Molecular informatics.